Life Sciences Opportunities in India & China: From Innovation to Commercialization
30 September 2009
China and India are emerging as major players in the life sciences industry. Both countries have a wealth of top talent as well as rapidly-improving resources for the industry. Both countries also constitute important current and potential markets for drugs, devices and diagnostics, and are also projected to be major sources of innovation in the not-too-distant future. This panel will explore the significant opportunities in China and India, in terms not only of expanding operations to both countries, but also in terms of working with innovative companies that originate from China and India.
Moderator:
- David A. Charapp, Special Counsel, Foley & Lardner LLP
Panelists:
- Stephen A. Bent, Partner, Foley & Lardner LLP
- Friedhelm Blobel, Ph.D., President, CEO, Director, SciClone Pharmaceuticals
- Kim Kamdar, Ph.D., Principal at Domain Associates
- Sanjay Shukla, M.D., M.S., Chief Executive Officer, RxMD
Related Insights
26 April 2024
Article
Increased Tariffs on Imports of Selected Products
As an additional measure to those taken last year, the Federal Government again modified the Law of General Import and Export Taxes (Ley de los Impuestos Generales de Importación y Exportación) in order to provide fair conditions to national industry and prevent bad practices in international trade, promoting the development of national industry and supporting the domestic market to balance the situation faced with the global market that has taken place as a consequence of the nearshoring phenomenon.
26 April 2024
Article
Non-Competes: What the FTC’s Rule May Mean for Health Care & Life Sciences Providers
On April 23, 2024, the U.S. Federal Trade Commission finalized a rule, by a vote of 3-2, abolishing the vast majority of employee covenants not to compete across the United States
03 May 2024
Events
Takeaways from the Trenches: the JetBlue/Spirit Merger Trial
Foley Partner Ben Dryden will moderate a panel for the ABA State Enforcement and the Mergers and Acquisitions Committees as they host a panel consisting of both enforcers and private practitioners, who will discuss the JetBlue/Spirit merger and what this decision may mean for the future of merger enforcement, including in the airline industry.